Stocktoria
Xenetic Biosciences, Inc. XBIO
Xenetic Biosciences, Inc. (XBIO) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.0M at a -90.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
FAQ
Is XBIO financially healthy?
Xenetic Biosciences, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does XBIO pay a dividend?
No, Xenetic Biosciences, Inc. does not currently pay a dividend.
How profitable is XBIO?
In FY2025, Xenetic Biosciences, Inc. had a net margin of -90.1% and a return on equity of -36.2%.
Is XBIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xenetic Biosciences, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.